Cryptocurrency
CNBC
Hims & Hers to offer generic semaglutide in Canada as Novo Nordisk patent lapses
Why This Matters
Novo Nordisk will lose its patent protection on its branded semaglutide drugs Ozempic and Wegovy in Canada after not paying a maintenance fee in 2019.
July 9, 2025
03:36 PM
4 min read
AI Enhanced
Positive
FinancialBooklet Analysis
AI-powered insights based on this specific article
Key Insights
- Merger activity often signals industry consolidation and potential valuation re-rating for similar companies
Questions to Consider
- Does this M&A activity signal industry consolidation or strategic repositioning?
Stay Ahead of the Market
Get weekly insights into market shifts, investment opportunities, and financial analysis delivered to your inbox.
No spam, unsubscribe anytime